Androgel (Testosterone) Patent Expiration, LOE Window & CMS Spending
Androgel (Testosterone) by Besins Healthcare Ireland: FDA Orange Book LOE 2026-10-12, 11 AB generics, $4.2M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Besins Healthcare Ireland |
| FDA Application & Pathway | N021015 (NDA) |
| Exclusivity / Cliff Horizon | Immediate Cliff (2025-2027) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2026-10-12 |
| Orange Book Patents (*PED Extensions) | 8 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 11 |
| 2024 CMS Total Public Spend | $4.2M |
| 2024 Medicare Part D Spend | $3.9M |
| 2024 Medicaid Spend | $286K |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |